362 results about "Osteo arthritis" patented technology

The invention discloses HA-PAS hydrogel for enhancing cartilage repair of early osteoarthritis and a preparation method of the HA-PAS hydrogel. According to the hydrogel, formylated hyaluronic acid, hydrazide modified low-methoxyl pectin and phenylboronic acid modified alginate form a ternary polysaccharide skeleton, a double-dynamic cross-linked network is formed through acylhydrazone bonds and boric acid ester bonds, and a triple network structure is formed by combining permanent cross-linking catalyzed by horse radish peroxidase. The hydrogel integrates functional components such as nano-selenium, a pulullan-strontium chelate and a mesenchymal stem cell source exosome, so that multiple effects of resisting oxidation, resisting inflammation, promoting cartilage differentiation and repairing subchondral bones are achieved. The compression modulus of the hydrogel is 0.8-1.5 MPa, and the hydrogel can be injected for in-situ gelling and MMP responsive degradation, shows an excellent cartilage repair effect in animal experiments, and provides a new solution for treatment of early osteoarthritis.

The invention relates to the technical field of biological medicines, and discloses a polypeptide for treating osteoarthritis by aiming at AHR (Aryl Hydrocarbon Receptor), the amino acid sequence of the polypeptide is GFQQSDVIHQSVYELISINHTEDRA, and the amino acid sequence of the polypeptide is GFQQSDVIHQSVYELISINHTEDRA, and the amino acid sequence of the polypeptide is GFQQSDVIHQSVYELISINHTEDRA. The polypeptide is prepared by a solid-phase polypeptide synthesis method; the solid-phase polypeptide synthesis method specifically comprises the following steps: synthesizing from a C end to an N end, connecting a carboxyl group of a first amino acid to insoluble resin, then adding other amino acids one by one to form a peptide chain, and carrying out protection and deprotection reactions of a side chain in each step. The polypeptide is composed of natural amino acids and has good biocompatibility and degradability, and experimental results show that no obvious toxic reaction occurs in the cell level and the animal level, so that the polypeptide has conditions for further development of pharmacokinetic research and preclinical tests, and a feasible basis is provided for conversion to clinical application.

The application provides an improved hyaluronic acid injection preparation for inflammation targeting and stem cell capture, a preparation method and use thereof, and belongs to the field of medicine. The injection preparation is prepared from unsaturated bond modified hyaluronic acid, stem cell targeting DNA tetrahedron and thiol modified inflammation targeting aptamer as raw materials. The injection preparation can be targeted to accumulate at an osteoarthritis site, capture mesenchymal stem cells in situ, recruit mesenchymal stem cells to the osteoarthritis site, promote differentiation of stem cells into cartilage, promote cartilage repair, play a role in treating osteoarthritis, and has a good application prospect.

Described herein are methods and compositions for using microbial agents (probiotics) and agents that promote growth of certain microbes (prebiotics) for management (including prevention and treatment) of musculoskeletal disorders, including osteoporosis, osteopenia, Paget's disease, stunting, osteoarthritis, osteomyelitis, and delayed or non-union fractures. Also described herein are methods and compositions for using probiotics and prebiotics for management of inflammation, and symptoms of menopause.

The invention belongs to the technical field of bioengineering and application thereof, and particularly relates to a laver compound zymolyte as well as a preparation method and application thereof. The compound enzyme is prepared through a compound enzymolysis process of protease and laver polysaccharide enzyme. Compared with a traditional single proteolysis process, a composite enzymolysis process of adding the high-enzyme-activity laver polysaccharide enzyme effectively breaks a'polysaccharide-protein 'composite structure of laver cell walls, so that the viscosity of zymolyte is reduced, high laver liquefaction rate and high product yield are realized, and the release efficiency of nutritional active ingredients is remarkably improved; the product is rich in low-molecular-weight polypeptide and oligomeric porphyra polysaccharide. The obtained zymolyte shows the comprehensive effects of improving joint activity, inhibiting osteophyte formation, adjusting cartilage metabolism balance and relieving inflammatory response in an osteoarthritis mouse model, and osteoarthritis is effectively relieved. According to the invention, efficient release and utilization of nutritional active ingredients of the laver are realized, and powerful technical support is provided for developing high-valued products, such as health-care products and functional foods, which have the function of maintaining joint health.

The present disclosure describes devices, methods and systems for modifying or altering gait kinematics via sensory augmentation and / or modifying muscle activation patterns via augmented motor learning to slow the progression of and / or reduce the pain associated with knee OA, particularly during gait (e.g., walking, running, stair climbing, etc.). Sensors can be used to measure gait parameters and characteristics and muscle activation patterns. Stimulation can be provided to the individual in order to promote learning new gait kinematics and muscle activation patterns.

Various embodiments are provided relating to caninized, feline, or equine antibodies that bind canine, feline, and / or equine IL23 and / or TNFα, including bispecific antibodies that bind both IL23 and TNFα. Such antibodies may be used alone or in combination in methods for treating canine, feline, and / or equine subjects with inflammatory conditions, such as inflammatory bowel disease (IBD), osteoarthritis, and inflammatory conditions such as gastroenteritis in dogs and cats.

The present invention relates to a composition comprising 4-hexylresorcinol (4-HR) as an active ingredient for prevention or treatment of a bone disease, and a formulation thereof. The composition comprising 4-hexylresorcinol (4-HR) as an active ingredient, or an ointment thereof was found to improve bone thickness, density, and strength and control bone remodeling by promoting the differentiation of osteoblasts and suppressing the proliferation and differentiation of osteoclasts in osteoporosis-induced animal models. Thus, the composition or ointment comprising 4-hexylresorcinol (4-HR) as an active ingredient can be provided as a therapeutic agent for bone diseases including bone fracture, osteoarthritis, rheumatoid arthritis, and osteoporosis.

The invention discloses a resource adaptive federated learning-based multi-modal knee osteoarthritis auxiliary diagnosis method, which comprises the following steps that: a server initializes a knee osteoarthritis diagnosis-oriented multi-modal model, and pre-deploys a low-rank adaptive plug-in in a trainable layer; after the client reports local hardware resources, the server allocates a resource echelon and issues a two-dimensional cutting proportion; the client performs depth and width cutting on the model based on the cutting proportion, activates a LoRA module of a specified layer, loads local knee joint X-ray images and clinical text data to perform multi-modal training, and establishes semantic mapping of image features and clinical description; the client only uploads and activates the LoRA parameter update quantity, and the server optimizes the global model through weighted average aggregation and key layer compensation; and in combination with real-time resource monitoring and knowledge distillation, the learning ability of the model for key discriminant features of knee osteoarthritis is enhanced. According to the method, heterogeneous computing power equipment is covered through a resource adaptive mechanism, and the participation efficiency of basic medical institutions is improved.

The present disclosure provides methods and compositions comprising hyaluronic acid (HA) hydrogel in combination with a saturated fatty acid for treating osteoarthritis. In some embodiments, aspects of the disclosure relate to pharmaceutical compositions comprising HA hydrogel in combination with a steroid. In some embodiments, the pharmaceutical compositions may be administrable via local, topical, and injection. In some embodiments, the pharmaceutical composition may be administrable by intra-articular injection.

The present disclosure is generally directed to treating a subject having osteoarthritis or confronting risk of developing osteoarthritis by administering an inhibitor of cartilage interlayer protein 2 (CILP2) to the subject.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of oleanolic acid in promoting chondrogenic differentiation of chondrocytes. This invention discovers that oleanolic acid promotes the expression of proteoglycans and calcium deposition in ATDC5 cells undergoing chondrogenic differentiation, and also promotes the expression of ATDC5 cell chondrogenic differentiation markers. Therefore, it has the potential to be formulated into a drug that can promote chondrogenic differentiation of chondrocytes, thereby promoting cartilage repair and regeneration for the treatment of osteoarthritis and rheumatoid arthritis.

The invention discloses an organic framework microgel for relieving osteoarthritis and application thereof.The organic framework microgel takes a cross-linked HAMA hydrogel network as a matrix and a skeleton of the whole microgel, and HAMA inherits and strengthens inherent excellent lubricating performance and biocompatibility of hyaluronic acid; according to the present invention, the HAMA matrix and the TA-ZIF-8 nano-particles are uniformly dispersed in the lubrication matrix so as to directly and enduringly improve the lubrication state of the joint, and the TA-ZIF-8 nano-particles are adopted as the treatment unit to be uniformly dispersed in the lubrication matrix, such that the matrix-wrapping structure ensures that the lubrication function (provided by the HAMA matrix) and the treatment function (provided by the TA-ZIF-8) can synchronously and continuously act in the whole period of the microgel retention in the joint cavity.

This invention relates to a multifunctional rehabilitation robot for knee osteoarthritis based on a rope-driven four-bar linkage structure, comprising a shell, a main control drive module, a knee joint wearable module, a knee joint connection and transmission module, and a detachable load-free module. The main control drive module is housed within the backpack shell. The knee joint wearable module includes a femoral wearable unit and a tibial wearable unit, connected via the knee joint connection and transmission module. The knee joint connection and transmission module includes a four-bar linkage structure and a rope drive assembly, which drives the four-bar linkage structure to achieve knee flexion and extension. The detachable load-free module includes a hip support unit and a leg support unit; the hip support unit is connected to the femoral wearable unit, and the leg support unit is connected to the tibial wearable unit. Compared with existing technologies, this invention effectively addresses the rehabilitation needs of patients with knee osteoarthritis and helps patients with varying degrees of varus / valgus aberration correction achieve assisted walking, load-free operation, rehabilitation training, and varus / valgus correction.

Administration of pentadecanoylcarnitine or pentadecanoic acid is provided for prevention, management or treatment of aggression, allergies, allergic rhinitis, Alzheimer's disease, anxiety and anxiety disorders, amyotrophic lateral sclerosis, arthritis, asthma, atherosclerosis, attention-deficit hyperactivity disorder, bipoloar disorder, brain damage, cancer, cardiovascular disease, cholestatic pruritis, depression, chronic obstructive pulmonary disease (COPD), cocaine abuse, cough, dermatitis, depression, drug-seeking behavior, gastrointestinal disorders, facial erythema associated with rosacea, glaucoma, hepatic diseases, hyperactive bladder, hypersensitivity disorders, hypertension, impulsivity, inflammation, mental disorders and conditions, metabolic disorders, migraines, nasal and sinus congestion, nausea, neuropathic pain with and symptoms of multiple sclerosis, neurological and neuropsychiatric disorders, obesity, obsessive-compulsive disorders, opioid-induced respiratory depression, osteoarthritis, pain, Parkinson disease, pathological gambling, peptic ulcers, schizophrenia, sleep disorders, spinal cord injury, tardive dyskinesia, tics and behavioral problems with Tourette's syndrome; as well as for supporting appetite, cardiovascular health, hematologic health, memory, metabolic health, mood, prolonged REM sleep, renal health, sexuality, sociability and metabolic, hematological, renal, and weight loss.

The utility model relates to the technical field of medical auxiliary instruments, and discloses a portable knee osteoarthritis rehabilitation physiotherapy instrument which comprises a main body, a physiotherapy pad is arranged on the inner side surface of the main body, an upper fixing pad is fixedly arranged on the right end face of the main body, a first hook-and-loop fastener is fixedly arranged on the outer surface of the upper fixing pad, and a second hook-and-loop fastener is fixedly arranged on the outer surface of the first hook-and-loop fastener. Through the arrangement of the storage battery, the device can have the function of storing electricity, the device is light and small, the device can be carried out, the practicability of the device is further improved, the controller can control on-off of current according to the temperature or time set by a user, and therefore heating control is achieved. The controller is provided with a temperature sensor and monitors the temperature of the physiotherapy pad in real time, when the temperature reaches a set value, the control circuit can automatically cut off current to prevent overheating, on the contrary, if the temperature is lower than the set value, the control circuit can recover current on-off, and therefore the effect of continuous heating of the electric heating wire is achieved.

The invention relates to the technical field of biological medicines, and particularly discloses application of emetine hydrochloride in preparation of a medicine for treating osteoarthritis. A cell test shows that the chondrocyte activity can be remarkably improved by an epecinol hydrochloride alkaline solution; animal model tests show that the epecinol hydrochloride alkali solution can maintain the steady state of chondrocyte metabolism, significantly reduce the cartilage injury degree of osteoarthritis mice and relieve osteoarthritis, and provides a new way for improving the osteoarthritis condition. The chemical structural formula of the emetine hydrochloride is shown in the specification.

Provided herein are methods of treating erosive hand osteoarthritis (OA) in a subject in need thereof, methods of reducing radiographic erosive progression, joint space narrowing, cartilage degradation, and / or bone formation in a subject in need thereof (e.g., a subject suffering from erosive hand OA), methods of inhibiting the development of new erosive joints in a subject in need thereof (e.g., a subject suffering from erosive hand OA), and methods of reducing pain in a subject with erosive hand OA. Also provided herein are uses of denosumab in the manufacture of a medicament adapted for use in a method described herein, as well as pharmaceutical compositions comprising denosumab for use in a method described herein.

A wearable device includes a first structure having a first band and a processor mounted on the first band, and a second structure having a second band configured to wrap around a knee and at least one sensor mounted on the second band and configured to measure vibration within the knee. The processor is programmed to make a determination whether the knee is within a range that indicates Osteoarthritis based on the vibration sensed by the at least one sensor, and to output the result to an external device.

Disclosed is a selenium-containing polyamino acid having a structure represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein A, B, D, E, m, n, and x are as defined in the description. Also disclosed is a pharmaceutical composition containing the selenium-containing polyamino acid or a pharmaceutically acceptable salt thereof. Also disclosed is a use of the selenium-containing polyamino acid or the pharmaceutically acceptable salt thereof, or the pharmaceutical composition containing the selenium-containing polyamino acid or the pharmaceutically acceptable salt thereof in the preparation of a drug for treating diseases selected from osteoarthritis, rheumatoid arthritis, and periodontitis. E[-(B)m-(A)n-D]x Formula (I)

The present application relates to the pharmaceutical use of 4-[9-(6-aminopurine)]-2(S)-hydroxybutyric acid methyl ester, in particular to its use in the preparation of a medicament for preventing and / or treating diseases associated with abnormal osteoclast activity. It has been found that 4-[9-(6-aminopurine)]-2(S)-hydroxybutyric acid methyl ester has a significant inhibitory effect on osteoclast differentiation, and intra-articular injection of 4-[9-(6-aminopurine)]-2(S)-hydroxybutyric acid methyl ester has a therapeutic effect on MIA-induced osteoarthritis. Therefore, 4-[9-(6-aminopurine)]-2(S)-hydroxybutyric acid methyl ester has the prospect of being developed into a therapeutic drug for diseases associated with abnormal osteoclast activity.

The invention provides a gene editing cell and a method for producing extremely high molecular weight hyaluronic acid by using the cell. The preparation method comprises the following steps: by taking PUC57 as a skeleton carrier, constructing a recombinant plasmid containing an HAS2 gene, and transfecting a mole NMRHas2 gene, a chicken CHICKHAS2 gene, an astronomy mouse SNMHAS2 gene, a dakalimeris mouse DMRHAS2 gene or a mole mouse BMRHAS2 gene into chicken fibroblasts through lipidosome to construct a stably transfected cell line, so that hyaluronic acid with extremely high molecular weight can be stably obtained. The method provided by the invention overcomes the defects of non-uniform molecular weight distribution of HA product sources, low molecular weight and single method in the prior art, and has important significance for developing medicines for treating osteoarthritis and novel medical equipment products.

The present disclosure provides recombinantly manufactured fusion proteins comprising a nerve growth factor (NGF) protein fragment or an analog thereof linked to a canine Fc fragment. Embodiments include the administration of the fusion proteins to patients to reduce pain symptoms in dogs suffering from a pain-associated ailment such as osteoarthritis. Exemplary Fc fusion proteins and pharmaceutical formulations of exemplary Fc fusion proteins are provided, in addition to methods of use and preparation.

The invention discloses a compound for regulating the activity of micro RNA-124, the compound has a structure as shown in a formula (I), and the compound can be used for preventing or treating inflammatory diseases. Comprising but not limited to inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, Alzheimer's disease, Paragins disease, osteoarthritis, atherosclerosis, ankylosing spondylitis, psoriasis, dermatitis, Sjogren syndrome, bronchitis, asthma and inflammation associated with colon cancer; the compounds are useful for treating colon cancer, and in particular inflammatory bowel disease, rheumatoid arthritis, Crohn's disease, ulcerative colitis, multiple sclerosis, osteoarthritis, ankylosing spondylitis, psoriasis, Sjogren syndrome, bronchitis, and inflammation associated with colon cancer.

The present application relates to a kind of preparation compositions containing the preparation method of loxoprofen derivative shown in general formula (I).The composition is a kind of analgesic antipyretic for preventing and treating rheumatoid arthritis, rheumatoid arthritis, osteoarthritis, joint deformity, gout, lumbago, neck shoulder wrist syndrome and periodontitis, cold, acute respiratory inflammation, such as postoperative inflammation of the diseases of the drug composition, its composition is characterized in that the mass percentage of loxoprofen derivative is 0.5%-5.0%w / w;Including physiologically acceptable crystal inhibitor;And at least one pH regulator.The pharmaceutical composition provided by the present application, compared with the preparation of loxoprofen derivative external preparation of the current existing technical means or the method reported in the public literature, solves the problem of active ingredient crystallization of such preparation, and achieves good effect.

The invention discloses hydrogel for repairing osteoarthritis as well as a preparation method and application of the hydrogel, and relates to the technical field of biological medicines. The hydrogel is prepared from polydeoxyribonucleotide and polyglutamic acid, the hydrogel has a porous structure, and the average pore size is 50-200 [mu] m. The preparation method comprises the following steps: mixing a PDRN solution with a PGA solution, then adding a cross-linking agent solution, uniformly stirring and mixing, and standing for reaction to form the hydrogel. The mechanical strength of the hydrogel can be improved after PDRN and PGA are crosslinked, meanwhile, PDRN can be slowly released in the hydrogel, the anti-inflammatory effect is achieved, and the obvious treatment effect on osteoarthritis is achieved.

The invention relates to an NEK7 inhibitor, a pharmaceutical composition and application of the NEK7 inhibitor. The NEK7 inhibitor has a structural formula as shown in a formula (I). The compound disclosed by the invention has good NEK7 inhibitory activity, and can be used for treating or preventing a plurality of inflammatory pathological diseases (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, atopic dermatitis, ulcerative colitis, Crohn's disease, cancer, osteoarthritis, gout and the like) regulated by NLRP3 inflammasome.

The application discloses application of long-chain non-coding RNA LncZFHX2 in preparation of a drug for treating osteoarthritis. LncZFHX2 is specifically combined with KLF4 protein through a specific structure and a base sequence of LncZFHX2, and promotes transcriptional regulation of the KLF4 protein on RIF1 protein. LncZFHX2 indirectly regulates RIF1 protein to improve a cell state. Overexpression of LncZFHX2 inhibits osteoarthritis in vitro. In the results of the examples of the application, it is verified that overexpression of LncZFHX2 inhibits development of osteoarthritis, and a new intervention approach and a candidate drug are provided for clinical prevention and treatment of osteoarthritis. LncZFHX2 has a short sequence, does not need to be translated into a protein to play a role, has the characteristics of quick effect, high efficiency and low cost, and has high cost performance in synthesis and application.

The present invention relates to novel heterocyclic compounds useful in the preparation of medicaments for the treatment of diseases associated with various functions of the histamine 4 receptor.In particular, said drugs are useful for treating inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itching, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritis pain, autoimmune disease, thyroid, immune-mediated (also known as type I) diabetes, lupus, post-surgical adhesions, vestibular disorders and cancer.